Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
University of Virginia
City of Hope Medical Center
Bristol-Myers Squibb
OHSU Knight Cancer Institute
University of South Florida
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
INSYS Therapeutics Inc
University of South Florida
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Aarhus
Pediatric Brain Tumor Consortium
Case Comprehensive Cancer Center
Pediatric Brain Tumor Consortium